MBX Biosciences falls after executive shakeup

MBX Biosciences

13/07/2026 21:30

** Shares of drug developer MBX Biosciences MBX.O fall 2.6% to $58.49 after the bell
** MBX names insider Steve Hoerter as new chief executive officer, succeeding Kent Hawryluk
** Appoints John Smither, interim finance chief since March 2026, as new chief financial officer
** All leadership changes are effective immediately
** MBX stock has nearly doubled so far this year



 (Reporting by Juby Babu in Mexico City)
 ((Juby.Babu@thomsonreuters.com;))